Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CD274 | Q9NZQ7 | 1/20 | 0.44 |
| ▸ | EGFR | P00533 | 1/20 | 0.43 |
| ▸ | ERBB3 | P21860 | 1/20 | 0.43 |
| ▸ | JAK1 | P23458 | 5/20 | 0.41 |
| ▸ | JAK2 | O60674 | 3/20 | 0.41 |
| ▸ | JAK3 | P52333 | 6/20 | 0.39 |
| ▸ | CDK2 | P24941 | 2/20 | 0.38 |
| ▸ | DYRK1B | Q9Y463 | 2/20 | 0.38 |
| ▸ | IGF1R | P08069 | 1/20 | 0.38 |
| ▸ | FGFR3 | P22607 | 4/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.37 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.37 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL374385 | 0.78 | EGFR (0.64) | CD274EGFRERBB3JAK1JAK2 | |
| SCHEMBL374409 | 0.73 | CD274 (0.59) | CD274JAK1JAK2JAK3IGF1R | |
| SCHEMBL20867687 | 0.72 | FGFR3 (0.68) | EGFRJAK2FGFR3 | |
| SCHEMBL374708 | 0.70 | HCK (0.58) | CD274EGFRERBB3JAK1JAK2 | |
| SCHEMBL374635 | 0.70 | CD274 (0.55) | CD274EGFRERBB3JAK1JAK2 | |
| SCHEMBL20867871 | 0.69 | MAPT (0.49) | MEN1KMT2A | |
| SCHEMBL373960 | 0.68 | EGFR (0.57) | EGFRERBB3MEN1KMT2AMAPK10 | |
| SCHEMBL22531924 | 0.68 | CD274 (0.53) | CD274EGFRERBB3JAK1JAK2 | |
| SCHEMBL20867677 | 0.67 | MEN1 (0.38) | MEN1KMT2A | |
| SCHEMBL4950163 | 0.66 | KDM1A (0.56) | CD274JAK1JAK2JAK3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10934311-B2 | Heterocyclic compound used as FGFR inhibitor | HANGZHOU INNOGATE PHARMA CO., LTD. (CN) | 2021-03-02 | — | — | US | disclosed |
| US-20190100531-A1 | HETEROCYCLIC COMPOUND USED AS FGFR INHIBITOR | HANGZHOU INNOGATE PHARMA CO., LTD. (CN) | 2019-04-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190100531-A1 | HETEROCYCLIC COMPOUND USED AS FGFR INHIBITOR | FGFR1, FGFR3, FGFR2 | CD274 579/4885EGFR 37/4885ERBB3 122/4885 |
| US-10934311-B2 | Heterocyclic compound used as FGFR inhibitor | FGFR1, FGFR3, FGFR2 | CD274 579/4885EGFR 37/4885ERBB3 122/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.